VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22‐HSVTk‐GFP triple fusion construct

Abstract

Based on our results, VP22 fusion proteins do not seem to traffic intercellularly at detectable levels in most tumor cell types. Even though VP22 enhanced cytotoxicity in one cell line in vitro, the effect in vivo was modest. Therefore, our results do not support the utility of VP22 as an enhancer of enzyme prodrug cancer gene therapy.